ENTA earnings analysis
What we found in ENTA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Enanta reported Q3 revenue of $14.359 million and diluted EPS of $(0.67), missing consensus revenue of $17.08664 million and EPS of $(0.48). Revenue fell from $17 million in Q2 2026 and $18 million in Q3 2025, while EPS deteriorated sequentially from $(0.45) but improved from $(0.85) a year earlier. The provided filing text contains no updated quantitative guidance, balance-sheet, cash-flow, or segment disclosures.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Declined Sequentially and Year Over Year
- Q3 revenue was $14.359 million, down approximately 15.4% from $17 million in Q2 2026 and 20.2% from $18 million in Q3 2025.
- EPS Missed Consensus
- Diluted EPS was $(0.67), compared with $(0.45) in Q2 2026 and $(0.85) in Q3 2025, representing a sequential deterioration but improvement versus the prior-year quarter.
- Quarter Missed Revenue and EPS Estimates
- Reported EPS of $(0.67) was $0.19 below the $0.48 consensus estimate, while revenue of $14.359 million was approximately $3.727 million below the $17.08664 million estimate.
- Controls Remained Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal control that materially affected, or were reasonably likely to materially affect, controls during the three months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No New Risk-Factor Changes Disclosed
- The company stated that there were no material changes to its previously disclosed risk factors during the three months ended June 30, 2026; therefore, the filing does not identify a newly elevated risk relative to the 2025 Form 10-K.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.67
What they said about what is next.
The provided 10-Q text does not include quantitative revenue or EPS guidance. Prior company commentary indicated sufficient liquidity through fiscal 2029, but no updated outlook is provided in the extracted filing text.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Enanta Pharmaceuticals reported Q2 2026 revenues of $17.2 million, reflecting a 15.4% increase from $14.9 million in Q2 2025. The net loss narrowed to $13.1 million compared to $22.6 million in the prior-year quarter,…
- 10-Q · February 11, 2026
- Enanta reported Q1 revenue of $18,615 (in thousands) and a narrower net loss of $11,938 (net loss per share $0.42) versus $22,290 a year ago (EPS -$1.05). Revenue and operating performance improved versus the prior-year…
- 10-Q · May 14, 2025
- Enanta reported Q3 (three months ended March 31, 2025) royalty revenue of $14,926,000 (down from $17,054,000 a year earlier) and GAAP diluted loss per share of $(1.06), which improved from $(1.47) in the prior-year…
- 10-K · November 22, 2023
- Enanta remains a royalty‑funded virology-focused discovery and development company with a cash‑rich balance sheet following a $200.0 million royalty sale to OMERS in April 2023. The company reported fiscal 2023 revenue…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ENTA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever